Development of the Extended Infusion Set and Its Mechanism of Action
- PMID: 35876264
- PMCID: PMC10973872
- DOI: 10.1177/19322968221112120
Development of the Extended Infusion Set and Its Mechanism of Action
Abstract
Continuous subcutaneous insulin infusion (CSII, or insulin pump) and continuous glucose monitoring (CGM) sensors have been increasingly used and associated with improved glycemic control by people with type 1 diabetes and insulin-requiring type 2 diabetes. Commonly used infusion sets in most CSII systems are limited to a wear time of 3 days. In contradistinction, CGM sensors are currently approved for seven and more days of wear. With the motivation to provide a 7-day infusion set that matches the CGM wear time and to improve patient experience, the recently CE-marked and FDA 510k-cleared Medtronic extended infusion set (EIS) was designed.s The EIS offers enhanced new features that include use for up to 7 days, improved convenience, comfort, and better quality of life for insulin pump users.
Keywords: CSII; extended wear; insulin infusion set; unexplained hyperglycemia.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The authors are all Medtronic employees.
Figures
Similar articles
-
Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.J Diabetes Sci Technol. 2009 Nov 1;3(6):1402-10. doi: 10.1177/193229680900300621. J Diabetes Sci Technol. 2009. PMID: 20144395 Free PMC article.
-
The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.JBI Libr Syst Rev. 2012;10(42 Suppl):1-10. doi: 10.11124/jbisrir-2012-170. JBI Libr Syst Rev. 2012. PMID: 27820140
-
Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.Diabetes Technol Ther. 2017 Jun;19(S3):S25-S37. doi: 10.1089/dia.2017.0035. Diabetes Technol Ther. 2017. PMID: 28585879 Free PMC article. Review.
-
Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study.Diabetes Technol Ther. 2021 Jan;23(1):51-58. doi: 10.1089/dia.2020.0030. Epub 2020 Sep 18. Diabetes Technol Ther. 2021. PMID: 32631081
-
Optimizing type 1 diabetes after multiple daily injections and capillary blood monitoring: Pump or sensor first? A meta-analysis using pooled differences in outcome measures.Diabetes Obes Metab. 2021 Nov;23(11):2521-2528. doi: 10.1111/dom.14498. Epub 2021 Aug 12. Diabetes Obes Metab. 2021. PMID: 34286892
Cited by
-
Impact of Infusion Set Materials and Designs on the Subcutaneous Response in People With Diabetes: A Rapid Review of the Literature.J Diabetes Sci Technol. 2023 Mar;17(2):314-321. doi: 10.1177/19322968221138076. Epub 2022 Nov 18. J Diabetes Sci Technol. 2023. PMID: 36398844 Free PMC article. Review.
-
Observational Study of the Impact of Infusion Set Replacement in Insulin Pump Users on Glycemic Management.J Diabetes Sci Technol. 2025 Jun 28:19322968251345837. doi: 10.1177/19322968251345837. Online ahead of print. J Diabetes Sci Technol. 2025. PMID: 40580090 Free PMC article.
-
Closed-loop therapy: recent advancements and potential predictors of glycemic outcomes.Expert Opin Drug Deliv. 2025 Jun;22(6):875-892. doi: 10.1080/17425247.2025.2492363. Epub 2025 Apr 18. Expert Opin Drug Deliv. 2025. PMID: 40231429 Free PMC article. Review.
-
The Future of Automated Insulin Delivery Systems.Endocr Pract. 2025 Jun 16:S1530-891X(25)00924-3. doi: 10.1016/j.eprac.2025.05.752. Online ahead of print. Endocr Pract. 2025. PMID: 40532759 Review.
-
Electrooxidation of Phenol on Polyelectrolyte Modified Carbon Electrodes for Use in Insulin Pump Infusion Sets.J Diabetes Sci Technol. 2024 May;18(3):625-634. doi: 10.1177/19322968221123083. Epub 2022 Sep 13. J Diabetes Sci Technol. 2024. PMID: 36112811 Free PMC article.
References
-
- Hoogma RP, Hammond PJ, Gomis R, et al.. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med. 2006;23(2):141-147. - PubMed
-
- Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765-774. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical